Top

FDA approves Senseonics’ implantable continuous glucose monitor

June 22, 2018

The FDA this week approved Senseonics‘ (NYSE:SENS) Eversense continuous glucose monitor for use in people ages 18 and older with diabetes.

The device is the first CGM system to feature an implantable sensor that can be worn for up to 90 days.

Senseonics’ Eversense device includes a small sensor that is implanted just below the skin in an outpatient procedure. It continuously measures glucose levels, sending that data to a mobile app every five minutes and alerting users if their glucose levels drop out of range.

Read More on Mass Device